#China

Japan approves a record ¥9.04 trillion defense budget for 2026. Under PM Takaichi, Japan hits its 2% GDP target early, focusing on the SHIELD unmanned system and hypersonic missiles.

Escalating border clashes between Tajikistan and the Taliban have resulted in the deaths of Chinese workers. Discover why ISKP is targeting foreign interests.

China has launched a national venture capital fund aimed at early-stage tech startups, potentially steering trillions of yuan into strategic industries across major regional hubs.

Trump's hesitation on Venezuela military action reveals a U.S. strategy to pressure the regime via sanctions while avoiding direct clashes with Russia and China.

China has opened a 6,000 sqm shopping center on Woody Island in the Paracels. This move signals a strategic shift toward normalizing civilian presence in the disputed South China Sea.

China's tobacco regulator has proposed new draft rules to limit e-cigarette production and investment to tackle excess capacity and fierce competition.

China imposes sanctions and asset freezes on US defense firms like Lockheed Martin over Taiwan arms sales, escalating geopolitical tensions and supply chain risks.

China has sanctioned 20 US defense firms, including Northrop Grumman and Boeing, in retaliation for a proposed $10 billion+ arms sale to Taiwan.

Japan's cabinet has approved a record $58 billion defense budget for 2026, aiming to counter threats from China by acquiring long-range missiles and a massive drone force.

In a world-first, surgeons in China successfully reattached a woman's severed ear by first grafting it to her foot. This radical approach to microsurgery could change how severe trauma injuries are treated.

In 2025, new leaders—Sanae Takaichi in Japan and Lee Jae Myung in South Korea—took power, setting the stage for a new era in bilateral relations. An analysis of the diplomatic, economic, and security issues.

AstraZeneca's $100 million upfront payment to China's Jacobio Pharma for a novel drug signals a major shift. The deal shows China's evolution from a generics maker to a key source of pharma innovation.